MicroRNAs are short non-coding RNAs expressed in different tissue and cell types that suppress the expression of target genes. As such, microRNAs are critical cogs in numerous biological processes 1, 2 , and dysregulated microRNA expression is correlated with many human diseases. Certain microRNAs, called oncomiRs, play a causal role in the onset and maintenance of cancer when overexpressed. Tumours that depend on these microRNAs are said to display oncomiR addiction [3] [4] [5] . Some of the most effective anticancer therapies target oncogenes such as EGFR and HER2; similarly, inhibition of oncomiRs using antisense oligomers (that is, antimiRs) is an evolving therapeutic strategy 6, 7 . However, the in vivo efficacy of current antimiR technologies is hindered by physiological and cellular barriers to delivery into targeted cells 8 .
Here we introduce a novel antimiR delivery platform that targets the acidic tumour microenvironment, evades systemic clearance by the liver, and facilitates cell entry via a non-endocytic pathway. We find that the attachment of peptide nucleic acid antimiRs to a peptide with a low pH-induced transmembrane structure (pHLIP) produces a novel construct that could target the tumour microenvironment, transport antimiRs across plasma membranes under acidic conditions such as those found in solid tumours (pH approximately 6), and effectively inhibit the miR-155 oncomiR in a mouse model of lymphoma. This study introduces a new model for using antimiRs as anti-cancer drugs, which can have broad impacts on the field of targeted drug delivery.
Silencing aberrantly expressed microRNAs (miRNAs) in vivo has been achieved using antisense with various nucleic acid analogues involving locked nucleic acids (LNAs), 29-O-methyl oligonucleotides (for example, antagomiRs), and peptide nucleic acids (PNAs) or nanoencapsulated PNAs 5, 9, 10 . As with most RNA-based therapies, each of these strategies is stymied by non-specific organ biodistribution, reticuloendothelial system clearance, and endolysosomal trafficking 8, 11 . Acidosis is a hallmark of tumours 12 . The pHLIP peptide forms an inducible transmembrane a-helix under acidic conditions 13 , has the ability to translocate membraneimpermeable molecules into cells via a non-endocytic route 13, 14 , and, when administered systemically, can target a variety of epithelial tumours 15 . Exploiting acidity as a general property of the tumour microenvironment, we find that the pHLIP peptide can localize to tumours of lymphoid origin in a subcutaneous flank model ( Fig. 1a ) and a model of disseminated lymphadenopathy (Fig. 1b) , while avoiding the liver. Although pHLIP also shows kidney targeting, much of the peptide is cleared by renal excretion (Extended Data Fig. 1 ). To exploit these targeting and delivery properties we developed a tumour-targeted antimiR delivery vector (pHLIP-antimiR).
PNAs are nucleic acid analogues comprising nucleobases joined by intramolecular amide bonds. This backbone imparts stability, nuclease resistance, and an increased binding affinity for complementary nucleic acids 16 . We hypothesized that pHLIP would facilitate the intracellular delivery of charge-neutral PNA antimiRs ( Fig. 1c ), which lack anionic phosphodiester groups, to cells within the tumour microenvironment. Tethering PNA antimiRs to pHLIP represents a unique approach because the multifunctional peptide component both targets tumours and mediates lipid membrane translocation 13 .
Fabrication of pHLIP-antimiR was verified by reversed-phase highperformance liquid chromatography (RP-HPLC), tricine SDS-polyacrylamide gel electrophoresis (SDS-PAGE), electrophoretic mobility shift assay (EMSA), and mass spectrometry (Extended Data Fig. 2a -c). In our constructs, the linkage between the PNA and peptide comprised a disulphide bond, which can be cleaved in the reducing environment of the cytosol ( Fig. 1c) 17 ; therefore, attachment to the inserting carboxy (C) terminus of pHLIP promotes the intracellular delivery of the PNA antimiR. When administered to A549 cells ( Fig. 2a and Extended Data Fig. 2d ) and Toledo diffuse large-B cell lymphoma (DLBCL) cells (Extended Data Fig. 2e , f), which express elevated levels of miR-155 compared with other DLBCL cells 18 , a pHLIP-antimiR modified with a 5-carboxytetramethylrhodamine (TAMRA) label attached to the PNA resulted in enhanced cellular delivery at acidic extracellular pH compared with neutral pH. PNA delivery to cells by pHLIP does not appear to be greatly affected by sequence since antimiR uptake has been demonstrated with numerous miRNAs including miR-182 ( Fig. 2a and Extended Data Fig. 2d ), miR-155 (Extended Data Fig. 2e, f miR-210. Delivery of antimiR-155 by pHLIP (pHLIP-anti155) derepressed luciferase in miR-155-overexpressing 19 KB cells that stably expressed a miR-155-targeted dual luciferase sensor (Extended Data Fig. 2g ). Additionally, inhibition of miR-155 by pHLIP-anti155 reduced KB cell viability at a dose comparable to LNA (15-base oligonucleotide, Exiqon) antimiR-155 delivered by lipofection ( Fig. 2b) . To demonstrate the adaptability of this antimiR delivery technology to silencing other miRNAs, pHLIP was attached to a PNA antimiR against miR-21, which de-repressed a miR-21 luciferase sensor (Extended Data Fig. 2h ). Together, these data suggest that pHLIP-antimiR is effective at delivering PNA antimiRs to multiple cancer cell types, in which endocytosis is hypothesized to be relegated to a supplementary mode of cell uptake due to the transport properties of pHLIP.
Certain oncomiRs have emerged as pharmacological targets. For example, ectopic expression of miR-155 in mice provided the first evidence that dysregulation of a single miRNA could cause cancer 20 . Although aberrant expression of miR-155 is characteristic of numerous cancers, miR-155 is notorious for its oncogenic involvement in lymphomas 21 . We previously developed a Tet-Off-based mouse model in which miR-155 expression is induced in haematological tissues and can be attenuated with the addition of doxycycline (DOX) 5 . Between 2 and 3 months of age, these mir-155 LSLtTA mice develop disseminated lymphoma, in which lymphoid tissues progress from normal histology, to follicular hyperplasia, to follicular lymphoma, to DLBCL (Extended Data Fig. 3a, b ). Although these are aggressive cancers comprising neoplastic B cells with a high Ki-67 proliferative index, the disease dramatically regresses upon DOX-induced miR-155 withdrawal (Extended Data Fig. 3b , c). Therefore, this is a model of oncomiR addiction in which tumorigenesis is dependent on expression of miR-155 and its removal leads to cancer regression 22 .
We assessed the therapeutic efficacy of pHLIP-anti155 in vivo using two tumour models based on mir-155 LSLtTA mice: (1) nude mice subcutaneously implanted with neoplastic B cells derived from the enlarged spleens of mir-155 LSLtTA mice (Extended Data Fig. 4a ) and (2) mir-155 LSLtTA mice after progression to conspicuous lymphadenopathy (Extended Data Fig. 4b ). Continuous suppression of miR-155 via DOX-impregnated mouse chow or a cocktail of chemotherapeutics and anti-inflammatory steroids (CHOP) served as positive controls that each caused tumour regression (Extended Data Fig. 5a ). Since CHOP is part of the current standard of care for human lymphomas 23 , the similar response to treatment with DOX and CHOP demonstrated the potential utility of antimiR-155 cancer therapy. Accordingly, intravenous administration of pHLIP-anti155 to the flank tumour model resulted in a significant reduction in tumour growth (Fig. 3a) . In a subsequent study at a higher dose, pHLIP-anti155 showed a significant survival advantage compared with a commercially available LNA (Exiqon) antimiR optimized for in vivo miR-155 silencing ( Fig. 3b and Extended Data Fig. 5b ). After administration of pHLIP-anti155, mice exhibited no clinical signs of distress, toxicity, and renal damage (Extended Data Fig. 5c ). Note that the dose of pHLIP-anti155 used in this study was much lower (ranging from 17-to 40-fold) than that used in other antimiR delivery reports 10, 24 .
In addition to delaying tumour growth, pHLIP-anti155 treatment suppressed the metastatic spread of neoplastic lymphocytes to other organs. The liver, lymph nodes, and spleen were common targets for metastatic lymphocytes. In a blinded pathological assessment, livers from mice treated with pHLIP-anti155 and DOX had rare scattered aggregates of one to three neoplastic lymphocytes, while livers in the negative control groups typically had dense tumoral aggregates of up to two dozen cells scattered throughout the entire organ ( Fig. 3c )-note that these tissues were harvested at an early endpoint (that is, when the negative controls reached a tumour size of 1 cm 3 , Fig. 3a ) in relation to the survival study ( Fig. 3b ) to resolve pharmacological effects. Early endpoint treatment with pHLIP-anti155, DOX, and CHOP reduced the onset of splenomegaly (as judged by spleen mass), which occurred in all of the negative control groups (Fig. 3d ). Additionally, pHLIP-anti155 significantly delayed the development of conspicuous lymphadenopathy (Fig. 3e ), which was particularly evident in the inguinal and axillary lymph nodes throughout all of the groups (Extended Data Fig. 5d ). 
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On the basis of a blinded complete blood count analysis, the negative control groups comprised a large number of atypical mononuclear cells of lymphoid origin-consistent with the leukaemic phase of lymphoma. Treatment with pHLIP-anti155 and DOX had levels of circulating lymphocytes similar to wild type, while CHOP treatment resulted in lymphocyte levels much lower than wild type (Extended Data Fig. 5e ). Although pHLIP can target to metastasized lymph node tumours (Extended Data Fig. 1c ), the therapeutic effects on the levels of circulating lymphocytes suggest that the lower incidence of metastatic spread is probably due to antimiR activity at the primary tumour. These findings support the effective targeting of systemic antimiR-155 therapy to neoplastic cells (Extended Data Fig. 5f ). The additional lymphopenia caused by CHOP treatment probably reflects the general toxicity of nontargeted conventional chemotherapy drugs (Extended Data Fig. 5e ). The absence of systemic toxicity may represent an important advantage for pHLIP-targeted antimiR therapy. Importantly, when healthy C57BL/6 mice were treated at the highest dose and frequency used in this study, pHLIP-anti155 showed no significant impairment of liver and kidney function (Extended Data Fig. 6a ). Additionally, white blood cell levels (Extended Data Fig. 6b ), body mass (Extended Data Fig. 6c ), and organ mass (Extended Data Fig. 6d ) were all within normal ranges.
In addition to the miR-155-addicted lymphoma subcutaneous tumour model, pHLIP-anti155 was also effective at treating KB cell xenograft tumours, which stably expressed luciferase for intravital monitoring of tumour bioluminescence (Extended Data Fig. 7 ), as well as disseminated tumours in mir-155 LSLtTA mice. Although implanted subcutaneous tumour models are effective for evaluating tumour growth, spontaneous cancer models arising in endogenous tissues are a more clinically relevant means of assessing therapeutic efficacy. Remarkably, systemically administered pHLIP-anti155 accumulated in the enlarged lymph nodes of the transgenic mir-155 LSLtTA mice (Fig. 4a ). Furthermore, like most therapeutics, PNA oligomers are known to be cleared by the reticuloendothelial system 11 , which results in accumulation in the liver; pHLIP-anti155 showed approximately 10-fold reduction in liver accumulation compared with anti155 alone (Fig. 4a and Extended Data Fig. 8a, b) . The therapeutic impact of pHLIP-anti155 in mir-155 LSLtTA mice was supported by a statistically significant decrease in spleen size and a nonstatistically significant reduction in lymph node tumour burden ( Fig. 4b and Extended Data Fig. 8c-e ). A non-statistically significant increase in apoptosis was also observed in the lymph nodes of treated mice (Extended Data Fig. 8f, g) . Interestingly, blinded histopathological analysis revealed that spleens in pHLIP-anti155-treated mir-155 LSLtTA mice had differentiated red and white pulp (similar to wild-type mice with no treatment), while the splenic architecture of mir-155 LSLtTA mice treated with pHLIPantiscr was almost completely effaced ( Fig. 4c and Extended Data Fig. 8h ). As with the subcutaneous tumour studies, pHLIP-anti155 treatment also showed a 12-fold reduction in liver metastasis ( Fig. 4d and Extended Data Fig. 8i, j) , while flow cytometric analysis revealed reductions in populations of B220-expressing spleen cells (Extended Data Fig. 8k ). Consistent with a lack of systemic toxicity, treatment with pHLIP-anti155 produced no histopathological kidney damage (Extended Data Fig. 8l ). Lastly, all mice that developed lymphoma-induced paresis showed improved motor skills after pHLIP-anti155 treatment ( Supplementary Videos 1-4, n 5 3) .
For a more direct assessment of miR-155 silencing in mir-155 LSLtTA mice, we monitored the levels of miR-155 targets in response to antimiR treatment. As an oncogene in lymphoma, miR-155 suppresses genes involved in processes such as apoptosis, proliferation, immune response regulation, as well as cell differentiation and development 21 . However, the addiction mechanisms by which lymphoma regresses upon miR-155 withdrawal are unknown. Typically, miR-155 targets have been identified by differential gene expression analysis of an overexpression condition compared with wild type 25 . To uncover the genes required for miR-155 addiction, we performed RNA sequencing (RNA-seq) analysis on miR-155-addicted lymphoid tumours compared with regressing tumours (Extended Data Fig. 9a ). This is the first study, to our knowledge, to identify miRNA cancer targets that directly result from oncomiR withdrawal. Out of 29,209 mouse genes, 2,101 showed significant upregulation or downregulation in response to miR-155 attenuation (Extended Data Fig. 9b and Supplementary Table 1 ). Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of upregulated genes revealed that 41% have been associated with cancer pathways (Extended Data Fig. 9c ). Additionally, 25% have been implicated in cell adhesion and migration pathways 
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such as leukocyte transendothelial migration. We compared the upregulated genes to known and putative miR-155 targets (Supplementary Table 2 ) identified using the miRWalk target prediction algorithm 26 . At the intersection of these screens, several genes are known to have tumour suppressor characteristics (Fig. 4e , Extended Data Fig. 9d and Supplementary Table 3 ). One notable gene is Bach1, a transcription factor that has been validated as a miR-155 target in renal cancer and cultured B cells 25, 27 . Gene expression analysis was used to validate Bach1 as a miR-155 target in Toledo cells treated with pHLIP-anti155 (Extended Data Fig. 9e ) and in mir-155 LSLtTA mice undergoing DOX-induced miR-155 withdrawal (Extended Data Fig. 10 ). Furthermore, diseased mir-155 LSLtTA mice treated with pHLIP-anti155 showed an increase in Bach1 levels in cancerous axillary, cervical, and inguinal lymph nodes (Fig. 4f) . A known miR-155 target in lymphoma, Mafb 24 , was also upregulated in response to pHLIP-anti155 treatment (Fig. 4f) . Therefore, pHLIP-anti155 can target lymph node neoplasms and cause effective blockage of miR-155 activity.
While oncomiRs are proving to be potent anticancer targets, in theory, using this approach, every miRNA is a 'druggable' target. Through targeted antagonism of miRNAs, pHLIP-antimiR has vast therapeutic potential for cancer and many other pathological conditions that produce localized acidic environments such as ischaemia, myocardial infarcts, stroke, tissue trauma, and sites of inflammation and infection. The main limitation of this transmembrane delivery approach involves the need for the drug cargo to have limited charge, such as PNA antimiRs. While other antimiR delivery and targeting strategies have been described 28, 29 , utilization of pHLIP to target the acidic tumour microenvironment is a widely applicable technology that will present new therapeutic and mechanistic opportunities for effective targeting of miRNA silencing.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
PNA synthesis. Regular Boc-protected PNA monomers were purchased from ASM Research Chemicals. All the given oligomers were synthesized on solid-support using standard Boc chemistry procedures 30 . The oligomers were cleaved from the resin using m-cresol:thioanisole:TFMSA:TFA (1:1:2:6) cocktail solution. The resulting mixtures were precipitated with ether (three times), purified, and characterized by RP-HPLC and MALDI-TOF, respectively. All PNA stock solutions were prepared using nanopure water and the concentrations were determined at 90 uC on a Cary 3 Bio spectrophotometer using the following extinction coefficients: 13,700 M 21 cm 21 (A), 6,600 M 21 cm 21 (C), 11,700 M 21 cm 21 (G), and 8,600 M 21 cm 21 (T). The 23base oligonucleotide PNA oligomer complementary to miR-155 has an estimated melting temperature (T m ) of 77.8 uC. Single-isomer 5-carboxytetramethylrhodamine (TAMRA) purchased from VWR was exclusively conjugated to the amino (N) terminus of PNAs with a hydrophilic bifunctional linker, Boc-miniPEG-3 Tm (11-amino-3,6,9-trioxaundecanoic acid, DCHA, denoted in the sequences by -ooo-) purchased from Peptide International. Cysteine was also conjugated to the C terminus of PNAs using a Boc-miniPEG-3 linker.
The following PNA antimiR sequences were used: anti155, TAMRA-ooo-ACC CCTATCACAATTAGCATTAA-ooo-Cys; antiscr, TAMRA-ooo-ACCCAATC GTCAAATTCCATATA-ooo-Cys; anti21, TAMRA-ooo-TCAACATCAGTCTG ATAAGCTA-ooo-Cys; anti182, TAMRA-ooo-CGGTGTGAGTTCTACCATTG CCAAA-ooo-Cys.
Full-length PNA antimiRs were used throughout this study. While current technologies such as 'tiny' LNAs have seen efficacy with miRNA seed-targeted 8-base oligonucleotide antimiRs 31 , truncated PNA antimiRs should be similarly effective owing to their high binding affinity, which can be further enhanced with chemical modifications 32 . Synthesis and characterization of pHLIP-antimiR. To generate pHLIP-antimiR constructs, the following pHLIP sequence (New England Peptide) was synthesized: AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT(CNPys)G; conjugation of the C terminus to thiolated-PNA was facilitated by incorporating a cysteine group derivatized with 3-nitro-2-pyridinesulphenyl (NPys). To synthesize pHLIP-antimiR constructs, pHLIP-Cys(NPys) and antimiR PNA (peptide:PNA 1:1.3) were reacted overnight in the dark in a mixture of DMSO/DMF/0.1 mM KH 2 PO 4 pH 4.5 (v/v 3:1:1) under argon. Note that this protocol was adapted from a general method of conjugating peptides to PNAs. Aside from pHLIP, attaching molecules, such as cell-penetrating peptides, to PNAs can increase cellular uptake and in vivo delivery efficacy 33, 34 . However, these conjugates typically require high doses and distribute to tissues throughout the body, which can result in off-target effects 11, 35 . Similarly, pHLIP can be attached to other antimiR compositions (such as LNA), which would probably improve tumour targeting; however, physicochemical properties of PNA make them more amenable to pHLIP-mediated membrane translocation. A750-pHLIP was fabricated as previously described 15 .
Purification and verification of pHLIP-antimiR. After conjugation, pHLIP-antimiR was purified by RP-HPLC (Shimadzu) using a C18 column and a mobile phase gradient of water and acetonitrile with 0.1% trifluoroacetic acid. Purified pHLIP-antimiR was further characterized using matrix-assisted laser desorption/ionizationtime of flight (MALDI-TOF). Concentrations of pHLIP-antimiR were determined on a Nanodrop Spectrophotometer (Thermo Scientific) at 260 nm corrected for peptide and TAMRA absorbance. Gelshift analysis used a 20% TBE gel and Bolt electrophoresis system (Life Technologies); before loading, samples were incubated with an equimolar amount of miR-155, denatured at 95 uC for 2 min, and allowed to anneal at 37 uC for 30 min. SYBR Gold (Life Technologies) was used to visualize miR-155; pHLIP and free PNA were not detected by the stain. Tricine SDS-PAGE used a 16% tricine gel (Life Technologies) and standard SDS-PAGE procedures. Samples were visualized first using TAMRA fluorescence on a Maestro 2 Multispectral Imaging System (PerkinElmer), and then using Simply Blue Coomassie stain (Life Technologies). For disulphide reduction studies, pHLIP-antimiR was reduced for 30 min in 200 mM DTT for HPLC and EMSA, and 5 mM TCEP for tricine SDS-PAGE. For all in vitro and in vivo studies, pHLIP-antimiR was heated at 65 uC for 10 min to prevent aggregation. Animals. All mice were maintained at Yale University in accordance with Yale Animal Resource Center and the Institutional Animal Care and Use Committee guidelines. The mir-155 LSLtTA mice were generated as previously described 5 . For transplant studies, 5-to 6-week-old female CrTac:NCr-Foxn1 nude mice (Taconic) were used. For toxicology studies, 8-to 9-week-old female C57BL/6J mice (Jackson) were used. For treatment of mir-155 LSLtTA mice, a sample size of at least four was appropriate on the basis of post hoc power analysis using quantitation of spleen size (Extended Data Fig. 8d ) with a 95% confidence interval. For all animal studies, group allocations were randomized and all pathological analyses were blinded to treatment groups and expected experimental outcomes. Cell culture. For all pH-controlled cell culture experiments, cells (previously tested for mycoplasma and supplied from ATCC) were incubated with 10% FBS in RPMI buffered at pH 7.4 with HEPES or pH 6.2 with MES, and treated with pHLIP-antimiR suspended in reaction buffer which constituted no more than 1% of the final volume. Histology and other techniques. Harvested tissues were fixed in 10% formalin and processed by Yale Pathology Tissue Services for H&E and terminal deoxynucleotidyltransferase-mediated dUTP nick end labelling (TUNEL) staining. Retro-orbitally collected whole blood preserved in EDTA or serum separated using lithium heparin was sent to Antech Diagnostics for complete blood count or clinical chemistry analyses, respectively. Image quantification used ImageJ version 1.47 (NIH) and Colour Deconvolution plugin (A. C. Ruifrok). Intravital and ex vivo fluorescence imaging was performed on either an IVIS Spectrum System (Caliper) or Maestro 2 Multispectral Imaging System using near-infrared or TAMRA filter sets. Live mice were anaesthetized using isoflurane during image acquisition. For whole-organ studies, organs were harvested and fixed in 10% formalin before imaging. Flank tumour establishment. To establish mir-155 LSLtTA lymphoma subcutaneous flank tumours, first enlarged spleens were extracted from 2-to 3-month-old mir-155 LSLtTA mice with obvious lymphadenopathy (which generally correlated with incidence of splenomegaly). Using a 100 mm pore-size cell strainer technique, spleen tissue was dispersed into a single cell suspension in 5% FBS in PBS on ice. Red blood cells were lysed using ammonium chloride lysis buffer (Stem Cell Technologies), and 5 3 10 6 cells were subcutaneously injected into nude mice. Tumours were generally palpable within 10 days; tumour volume was calculated as (length 3 width 2 )/2.
For bioluminescent xenograft tumours, KB cells were stably transfected with firefly luciferase and clonally selected via hygromycin B selection; 5 3 10 6 cells were subcutaneously injected into nude mice to establish tumours. RediJect D-Luciferin Ultra Bioluminescent Substrate (PerkinElmer) was administered via the manufacturer's protocol for intravital monitoring of tumour bioluminescence using IVIS Spectrum (Caliper). It was pre-established that, for all flank tumour studies, animals were excluded if their tumours had not reached a volume of 50-100 cm 3 by the time of treatment. Animals were randomized into experimental arms by minimizing the differences in mean tumour size and standard deviation. Confocal imaging and flow cytometry. For fixed cell confocal preparation, after treatment for 1 h at with 5 mM of pHLIP-anti155 ( Fig. 2a ), cells were washed with 1% BSA in PBS, fixed in 4% paraformaldehyde, and permeabilized using 0.1% Triton X-100 in PBS. All washes were performed using PBS at pH 7.4 to wash away surface-bound pHLIP. Actin and nuclei were stained with Texas Red-X phalloidin (Life Technologies) and Hoechst 33342 (Life Technologies), respectively. Cells were mounted in Slow Fade Gold (Invitrogen). Alternatively, Toledo cells were treated with 500 nM pHLIP-anti155 (Extended Data Fig. 2e ), washed with 1% BSA in PBS, and imaged live without fixation or permeabilization. For tumour and liver tissues, organs were harvested and fixed in 10% formalin, then incubated overnight in 30% sucrose in PBS. Tumours were flash frozen in OCT before being slicing into 10 mm sections, permeabilized, stained, and mounted in Vectashield (Vector Labs). Cell and tissue confocal imaging used a TCS SP5 Spectral Confocal Microscope (Leica); confocal projections were constructed using LAS AF software (Leica) with 0.9-mmstack height. For live cell flow cytometry, after 48 h of treatment, cells were washed five times with 1% BSA in PBS on ice and then analysed on a FACScan (BD Biosciences) using FlowJo software (Tree Star); for B220 studies, freshly harvested spleen cells (see section on Flank tumour establishment) were blocked with 10% FBS (20 min), stained with Alexa488-anti-CD45R/B220 (BD clone RA3-6B2, 20 min incubation at room temperature at 1 mg m1 2l concentration), washed three times with PBS on ice, and transferred to 1% BSA 0.1% NaN 3 in PBS on ice before analysis. Luciferase reporter and cell viability. For dual luciferase reporter experiments, the miRNA sensor was generated by inserting the target sequence for miR-155 into the 39 untranslated region of Renilla luciferase on a psiCHECK-2 vector (Promega). KB cells were stably transfected using Lipofectamine 2000 (Life Technologies) and co-transfection with a Linear Hygromycin Marker (Clontech) followed by clonal selection. Utilization of stable clones was more reliable than transiently transfected cells for antimiR studies. Cell lysates were measured for luciferase activity 48 h after treatment using the Dual-Luciferase Reporter Assay System (Promega). Control LNA antimiR-155 (Exiqon) was delivered by lipofectamine RNAiMAX. Optimal sensor activity was seen at a 500 nM dose, although inhibition of miR-155 was also observed at lower doses. For analysis of miR-21 inhibition A549 cells were similarly treated with pHLIP-anti21 and relevant controls; however, the cells were instead transfected with a miR-21-specific LightSwitch miRNA Target GoClone Luciferase Reporter (Active Motif). Cell viability was measured 96 h after treatment using CellTiter-Glo (Promega). For both luciferase and viability assays, all treatments were performed at the indicated pH for 24 h, then media was replaced with 10% FBS in RPMI at physiological pH for extended incubation. qPCR. For qPCR analysis of tissue after treatment with two 2 mg kg 21 injections of pHLIP-anti155 or pHLIP-antiscr spaced 48 h apart, tissues were harvested 24 h after the last injection and divided into at least five representative 1 mg slices. Tissue slices were pooled into Trizol (Life Technologies) and homogenized using a Precellys 24
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Homogenizer. As per the manufacturer's protocol, chloroform was added to facilitate phase separation, and the RNA-containing aqueous phase was collected. An equal volume of 200 proof ethanol was added, and RNA was purified from this mixture using RNeasy kit (Qiagen) and standard procedures with on-column DNase I digestion; standard RNeasy purification was followed for RNA extraction from cells. Reverse transcription PCR was performed with 1 mg total RNA and poly-A based iScript cDNA Synthesis Kit (Bio-Rad). Real-time PCR was performed with Quantitect Primer Assays (Qiagen) and iQ SYBR Green Supermix (Bio-Rad) using a Roche LightCycler 480 System; all samples were normalized to b-actin. RNA-seq. For RNA-seq analysis, the overexpression and withdrawal groups both consisted of three mice with subcutaneous tumours that were established from enlarged spleens of diseased donor mir-155 LSLtTA mice (Extended Data Fig. 9a ). The overexpression and withdrawal mice were paired such that each of the three pairs was from a separate donor littermate. Tissue was harvested once tumours reached a volume of 1 cm 3 ; for mice in the miR-155 withdrawal group, DOX was administered for 16 h before tissue collection. As described in the transplant methods, tumour tissue was dispersed into a single cell suspension and red blood cells were lysed. Total RNA was extracted from the remaining cells using the hybrid Trizol and RNeasy protocol described in the qPCR methods. High-quality total RNA (Agilent 2100 Bioanalyzer RIN value greater than 7) was sent to Expression Analysis for library preparation, Illumina TruSeq mRNA sequencing (50-base-pair paired end, 25 million reads per sample), alignment to the mouse genome (greater than 80% aligned to the NCBI37/mm9 assembly), and counts of the number of gene-mapped fragments given the maximum likelihood abundances. DESeq was used first to estimate size factors (that is, normalize samples by their respective sizes) and dispersions (that is, variance between samples), and then to identify differentially expressed genes (Supplementary Table 1 ). Heat maps were generated using variance stabilizing transformations of the count data on the basis of a parametric fit to the overall mean dispersions. KEGG analysis. The Database for Annotation, Visualization and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov) was used to identify the KEGG pathways that were enriched in the genes and both upregulated in response to miR-155 withdrawal and having a false discovery rate less than 0.05. Enriched KEGG pathways had a minimum count threshold of 2 and a modified Fisher's exact P value for gene enrichment less than 0.05. 15 . Similarly, we speculate that the increased uptake of pHLIP peptide in the kidneys is due to excretion and increased acidity of renal tubule cells. Initially kidneys are highly enriched for pHLIP, which is gradually excreted while pHLIP shows a more steady accumulation in the tumour. b, Representative example showing A750-pHLIP distribution to the (white arrow) bladder and (yellow arrow) enlarged axillary lymph node 36 h after intravenous administration into mir-155 LSLtTA mice with lymphadenopathy (n 5 3). c, In addition to distributing to the (white arrow) primary mir-155 LSLtTA flank tumour and (red arrow) kidneys, A750-pHLIP distributes to (black arrows) enlarged lymph nodes that resulted from metastatic spread; intravital fluorescence of A750-pHLIP was detected 48 h after intravenous injection into nude transplant mice with conspicuous lymphadenopathy (a representative animal from n 5 3 is shown).

